Biogen ups investment in biosimilars

Biogen Inc. said it plans to make a $100 million upfront payment to Samsung Bioepis to acquire the rights to commercialize biosimilar versions of Lucentis and Eylea, two blockbuster eye drugs. Samsung Bioepis is a joint venture founded in 2012 between the Cambridge, Mass.-based biotech and Samsung , the Korean conglomerate. Biogen said it will record a $65 million charge to its research and development expenses as a result of the transaction, which also includes potential additional milestone payments of up to $210 million. Biogen’s stock is down 2.9% for the year, while the S&P 500 is up 23%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Author: | Source

This article does not constitute investment advice. We are not affiliated or responsible for content hosted on 3rd-party sites in any way.

Click here for great deals & savings!